Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings
LONDON, Jan. 17, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces ...
Autolus Therapeutics presents clinical data updates at Tandem Meetings
Autolus Therapeutics (AUTL) announces an oral presentation and three poster presentations accepted to the 2025 Tandem Meetings ...
ETF Daily News2d
Avanza Fonder AB Acquires Shares of 31,770 Autolus Therapeutics plc (NASDAQ:AUTL)
Avanza Fonder AB bought a new position in shares of Autolus Therapeutics plc (NASDAQ:AUTL – Free Report) during the fourth quarter, according to its most recent filing with the SEC.The fund ...
Business Insider6d
Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings
LONDON, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed ...
Nasdaq6d
Autolus Therapeutics to Present Data at 2025 Tandem Meetings on AUCATZYL® and Its Economic Impact Compared to CAR-T Therapies
Autolus Therapeutics received acceptance for an oral presentation and three poster presentations at the prestigious 2025 Tandem Meetings, highlighting their commitment to disseminating research ...
ETF Daily News5d
JPMorgan Chase & Co. Has $4.66 Million Stock Holdings in Autolus Therapeutics plc (NASDAQ:AUTL)
JPMorgan Chase & Co.’s holdings in Autolus Therapeutics were worth $4,663,000 at the end of the most recent quarter. Other large investors have also recently bought and sold shares of the company.
Mena FN6d
Autolus Therapeutics Presents Clinical Data Updates At The 2025 Tandem Meetings
(MENAFN- GlobeNewsWire - Nasdaq) LONDON, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company ...